Therapeutics in OAS

We studied the overlap between the antibodies post phase-I clinical trials and naturally sourced NGS sequences collected by Observed Antibody Space (OAS). You can read about it in the pre-print here. Scroll down for an interactive visualization of the variable region and CDR alignemnts together with a table with detailed alignments.

Variable Region Alignments Graph

Below you can see the best matches we could find to 242 Clinical Stage Therapeutic Antibodies (from Raybould et al. 2019) to variable regions in OAS. You can browse the best matches using the interactive chart below, as well as search through the table of actual alignments.

Legend: Fully Human Chimeric Humanized Mouse

CDR Alignments Graph

Below you can see the best matches we could find to 242 Clinical Stage Therapeutic Antibodies (from Raybould et al. 2019) to CDRs in OAS. You can browse the best matches using the interactive chart below, as well as search through the table of actual alignments.

Legend: Fully Human Chimeric Humanized Mouse

Alignments Table

Below you can explore the closest matches to therapeutic antibodies in OAS.

NameH-identity(%) (source)L-identity(%) (source)H-CDRs-identity(%) (source)L-CDRs-identity(%) (source)CDR-H3-identity(%) (source)Sequence Alignment
Ianalumab 90 (Palanichamy et al., (2014)) 88 (Zhu et al., (2013)) 78 (Galson et al., (2015)) 73 (Zhu et al., (2013)) 71 (Briney et al., (2019)) Show Alignments
Clazakizumab 80 (Vergani et al., (2017)) 87 (Gupta et al., (2017)) 65 (Banerjee et al., (2017)) 57 (Vander Heiden et al., (2017)) 78 (Banerjee et al., (2017)) Show Alignments
Concizumab 88 (Greiff et al., (2017)) 91 (Soto et al., (2016)) 80 (Greiff et al., (2017)) 95 (Wesemann et al., (2013)) 85 (Greiff et al., (2017)) Show Alignments
Tocilizumab 81 (Vergani et al., (2017)) 92 (Zhou et al., (2013)) 82 (Collins et al., (2015)) 100 (Cui et al., (2016)) 83 (Corcoran et al., (2016)) Show Alignments
Indusatumab 92 (Vergani et al., (2017)) 96 (Wu et al., (2015)) 82 (Ellebedy et al., (2016)) 100 (Gupta et al., (2017)) 84 (Levin et al., (2017)) Show Alignments
Indatuximab 89 (Greiff et al., (2015)) 95 (Cui et al., (2016)) 87 (Greiff et al., (2017)) 94 (Cui et al., (2016)) 100 (Greiff et al., (2017)) Show Alignments
Brazikumab 96 (Vergani et al., (2017)) 96 (Doria-Rose et al., (2015)) 90 (Briney et al., (2019)) 95 (Gupta et al., (2017)) 94 (Zhu et al., (2013)) Show Alignments
Anetumab 90 (Vergani et al., (2017)) 92 (Schanz et al., (2014)) 82 (Setliff et al., (2018)) 73 (Schanz et al., (2014)) 84 (Setliff et al., (2018)) Show Alignments
Futuximab 95 (Collins et al., (2015)) 92 (Cui et al., (2016)) 87 (Greiff et al., (2017)) 88 (Corcoran et al., (2016)) 81 (Greiff et al., (2017)) Show Alignments
Drozitumab 89 (Vergani et al., (2017)) 96 (Soto et al., (2016)) 80 (Galson et al., (2015)) 90 (Bhiman et al., (2015)) 85 (Galson et al., (2016)) Show Alignments
Denosumab 89 (Vergani et al., (2017)) 98 (Schanz et al., (2014)) 87 (Levin et al., (2017)) 100 (Huang et al., (2016)) 80 (Levin et al., (2017)) Show Alignments
Guselkumab 91 (Joyce et al., (2016)) 94 (Zhu et al., (2013)) 80 (Ellebedy et al., (2016)) 82 (Bhiman et al., (2015)) 90 (Prohaska et al., (2018)) Show Alignments
Polatuzumab 77 (Vergani et al., (2017)) 90 (Gupta et al., (2017)) 80 (Greiff et al., (2014)) 95 (Cui et al., (2016)) 80 (Greiff et al., (2017)) Show Alignments
Domagrozumab 91 (Vergani et al., (2017)) 89 (Wu et al., (2015)) 92 (Greiff et al., (2015)) 100 (Cui et al., (2016)) 88 (Greiff et al., (2017)) Show Alignments
Simtuzumab 84 (Greiff et al., (2017)) 90 (Cui et al., (2016)) 92 (Greiff et al., (2017)) 100 (Cui et al., (2016)) 100 (Briney et al., (2019)) Show Alignments
Berlimatoxumab 90 (Vergani et al., (2017)) 95 (Soto et al., (2016)) 89 (Briney et al., (2019)) 83 (Gupta et al., (2017)) 90 (Briney et al., (2019)) Show Alignments
Rontalizumab 77 (Joyce et al., (2016)) 88 (Schanz et al., (2014)) 76 (Briney et al., (2019)) 95 (Cui et al., (2016)) 90 (Soto et al., (2016)) Show Alignments
Bleselumab 90 (Vander Heiden et al., (2017)) 98 (Soto et al., (2016)) 80 (Jiang et al., (2013)) 100 (Doria-Rose et al., (2015)) 84 (Briney et al., (2019)) Show Alignments
Eldelumab 89 (Vergani et al., (2017)) 100 (Doria-Rose et al., (2015)) 81 (Gupta et al., (2017)) 100 (Doria-Rose et al., (2015)) 94 (Briney et al., (2019)) Show Alignments
Vedolizumab 81 (Palanichamy et al., (2014)) 88 (Soto et al., (2016)) 86 (Greiff et al., (2017)) 95 (Cui et al., (2016)) 85 (Greiff et al., (2015)) Show Alignments
Lorvatuzumab 89 (Corcoran et al., (2016)) 92 (Soto et al., (2016)) 88 (Greiff et al., (2014)) 86 (Cui et al., (2016)) 100 (Corcoran et al., (2016)) Show Alignments
Erenumab 88 (Vergani et al., (2017)) 99 (Gupta et al., (2017)) 71 (Levin et al., (2017)) 100 (Doria-Rose et al., (2015)) 82 (Levin et al., (2017)) Show Alignments
Efalizumab 76 (Vergani et al., (2017)) 94 (Corcoran et al., (2016)) 83 (Greiff et al., (2015)) 100 (Cui et al., (2016)) 85 (Khan et al., (2016)) Show Alignments
Imgatuzumab 85 (Vergani et al., (2017)) 90 (Gupta et al., (2017)) 68 (Soto et al., (2016)) 76 (Corcoran et al., (2016)) 92 (VanDuijn et al., (2017)) Show Alignments
Derlotuximab 96 (Greiff et al., (2017)) 100 (Rettig et al., (2018)) 89 (Greiff et al., (2017)) 100 (Cui et al., (2016)) 92 (Greiff et al., (2017)) Show Alignments
Depatuxizumab 80 (Meng et al., (2017)) 88 (Rettig et al., (2018)) 76 (Greiff et al., (2017)) 94 (Cui et al., (2016)) 88 (Khan et al., (2016)) Show Alignments
Ligelizumab 80 (Vergani et al., (2017)) 88 (Wu et al., (2015)) 71 (Greiff et al., (2017)) 88 (Cui et al., (2016)) 81 (Greiff et al., (2017)) Show Alignments
Gedivumab 83 (Vergani et al., (2017)) 93 (Gupta et al., (2017)) 67 (Briney et al., (2019)) 80 (Doria-Rose et al., (2015)) 55 (Levin et al., (2017)) Show Alignments
Crizanlizumab 80 (Tipton et al., (2015)) 91 (Gupta et al., (2017)) 90 (Collins et al., (2015)) 86 (Cui et al., (2016)) 93 (Greiff et al., (2017)) Show Alignments
Otelixizumab 91 (Vergani et al., (2017)) 71 (Schanz et al., (2014)) 82 (VanDuijn et al., (2017)) 75 (Schanz et al., (2014)) 83 (Greiff et al., (2017)) Show Alignments
Bevacizumab 77 (Vergani et al., (2017)) 93 (Schanz et al., (2014)) 90 (Corcoran et al., (2016)) 88 (Ota et al., (2010)) 93 (Corcoran et al., (2016)) Show Alignments
Tremelimumab 97 (Gupta et al., (2017)) 97 (Soto et al., (2016)) 94 (Briney et al., (2019)) 94 (Gupta et al., (2017)) 88 (Levin et al., (2017)) Show Alignments
Veltuzumab 85 (Greiff et al., (2015)) 82 (Wu et al., (2015)) 90 (Greiff et al., (2017)) 94 (Cui et al., (2016)) 92 (Greiff et al., (2017)) Show Alignments
Tabalumab 97 (Corcoran et al., (2016)) 99 (Doria-Rose et al., (2015)) 96 (Galson et al., (2015)) 100 (Doria-Rose et al., (2015)) 100 (Briney et al., (2019)) Show Alignments
Olokizumab 82 (Vergani et al., (2017)) 90 (Zhou et al., (2013)) 65 (Greiff et al., (2017)) 72 (Corcoran et al., (2016)) 81 (Ellebedy et al., (2016)) Show Alignments
Cixutumumab 94 (Tipton et al., (2015)) 94 (Soto et al., (2016)) 89 (Briney et al., (2019)) 85 (Doria-Rose et al., (2015)) 82 (Briney et al., (2019)) Show Alignments
Idarucizumab 77 (Vergani et al., (2017)) 91 (Wesemann et al., (2013)) 83 (Greiff et al., (2017)) 95 (Wesemann et al., (2013)) 87 (Greiff et al., (2017)) Show Alignments
Brentuximab 93 (Corcoran et al., (2016)) 98 (Rettig et al., (2018)) 96 (Greiff et al., (2017)) 100 (Fisher et al., (2017)) 100 (Corcoran et al., (2016)) Show Alignments
Setoxaximab 89 (Collins et al., (2015)) 96 (Cui et al., (2016)) 85 (Greiff et al., (2017)) 100 (Cui et al., (2016)) 91 (Greiff et al., (2015)) Show Alignments
Fresolimumab 85 (Palanichamy et al., (2014)) 95 (Zhou et al., (2013)) 62 (Galson et al., (2015)) 89 (Schanz et al., (2014)) 84 (Greiff et al., (2017)) Show Alignments
Anrukinzumab 89 (Vergani et al., (2017)) 87 (Vander Heiden et al., (2017)) 85 (Greiff et al., (2015)) 90 (Cui et al., (2016)) 91 (Corcoran et al., (2016)) Show Alignments
Alemtuzumab 76 (Liao et al., (2013)) 90 (Soto et al., (2016)) 80 (Greiff et al., (2017)) 66 (Corcoran et al., (2016)) 91 (Greiff et al., (2017)) Show Alignments
Omalizumab 75 (Palanichamy et al., (2014)) 90 (Wu et al., (2015)) 76 (Greiff et al., (2017)) 100 (Rettig et al., (2018)) 71 (Galson et al., (2016)) Show Alignments
Figitumumab 90 (Vergani et al., (2017)) 96 (Zhou et al., (2013)) 91 (Levin et al., (2017)) 100 (Gupta et al., (2017)) 88 (Levin et al., (2017)) Show Alignments
Abituzumab 83 (Greiff et al., (2017)) 89 (Schanz et al., (2014)) 85 (Greiff et al., (2017)) 100 (Cui et al., (2016)) 90 (Greiff et al., (2015)) Show Alignments
Benralizumab 79 (Corcoran et al., (2016)) 89 (Zhou et al., (2013)) 83 (Corcoran et al., (2016)) 83 (Cui et al., (2016)) 71 (Greiff et al., (2017)) Show Alignments
Durvalumab 96 (Vergani et al., (2017)) 98 (Sheng et al., (2017)) 90 (Galson et al., (2015)) 94 (Gupta et al., (2017)) 92 (Briney et al., (2019)) Show Alignments
Daratumumab 92 (Soto et al., (2016)) 100 (Doria-Rose et al., (2015)) 83 (Briney et al., (2019)) 100 (Doria-Rose et al., (2015)) 86 (Briney et al., (2019)) Show Alignments
Ibalizumab 86 (Greiff et al., (2015)) 92 (Wesemann et al., (2013)) 87 (Collins et al., (2015)) 95 (Cui et al., (2016)) 80 (Greiff et al., (2015)) Show Alignments
Enfortumab 98 (Corcoran et al., (2016)) 98 (Zhou et al., (2013)) 96 (Corcoran et al., (2016)) 100 (Doria-Rose et al., (2015)) 100 (Levin et al., (2017)) Show Alignments
Farletuzumab 78 (Vergani et al., (2017)) 82 (Sheng et al., (2017)) 96 (Greiff et al., (2017)) 90 (Cui et al., (2016)) 100 (Greiff et al., (2017)) Show Alignments
Epratuzumab 79 (Greiff et al., (2015)) 84 (Cui et al., (2016)) 84 (Greiff et al., (2017)) 95 (Cui et al., (2016)) 88 (Greiff et al., (2017)) Show Alignments
Roledumab 81 (Vergani et al., (2017)) 89 (Soto et al., (2016)) 68 (Vergani et al., (2017)) 94 (Doria-Rose et al., (2015)) 73 (Briney et al., (2019)) Show Alignments
Lenzilumab 91 (Vergani et al., (2017)) 91 (Schanz et al., (2014)) 78 (Briney et al., (2019)) 83 (Vander Heiden et al., (2017)) 83 (Tipton et al., (2015)) Show Alignments
Utomilumab 92 (Palanichamy et al., (2014)) 89 (Doria-Rose et al., (2015)) 88 (Meng et al., (2017)) 55 (Bhiman et al., (2015)) 100 (Greiff et al., (2015)) Show Alignments
Ascrinvacumab 96 (Vergani et al., (2017)) 100 (Zhou et al., (2013)) 96 (Liao et al., (2013)) 100 (Gupta et al., (2017)) 100 (Tipton et al., (2015)) Show Alignments
Sarilumab 90 (Vergani et al., (2017)) 99 (Gupta et al., (2017)) 88 (Galson et al., (2015)) 100 (Gupta et al., (2017)) 100 (Jiang et al., (2013)) Show Alignments
Etaracizumab 86 (Vergani et al., (2017)) 87 (Zhu et al., (2013)) 84 (Greiff et al., (2015)) 88 (Fisher et al., (2017)) 90 (Khan et al., (2016)) Show Alignments
Panobacumab 85 (Vergani et al., (2017)) 100 (Doria-Rose et al., (2015)) 84 (Briney et al., (2019)) 100 (Doria-Rose et al., (2015)) 80 (Vergani et al., (2017)) Show Alignments
Margetuximab 87 (Greiff et al., (2017)) 94 (Rettig et al., (2018)) 82 (Greiff et al., (2017)) 94 (Ota et al., (2010)) 84 (Khan et al., (2016)) Show Alignments
Patritumab 96 (Liao et al., (2013)) 97 (Zhu et al., (2013)) 92 (Galson et al., (2015)) 95 (Doria-Rose et al., (2015)) 90 (Wu et al., (2015)) Show Alignments
Golimumab 93 (Vergani et al., (2017)) 99 (Doria-Rose et al., (2015)) 88 (Galson et al., (2015)) 94 (Doria-Rose et al., (2015)) 94 (Briney et al., (2019)) Show Alignments
Nimotuzumab 75 (Vergani et al., (2017)) 81 (Zhou et al., (2013)) 68 (Wu et al., (2015)) 95 (Cui et al., (2016)) 62 (Doria-Rose et al., (2015)) Show Alignments
Tarextumab 89 (Vergani et al., (2017)) 94 (Zhou et al., (2013)) 75 (Briney et al., (2019)) 89 (Gupta et al., (2017)) 75 (Ellebedy et al., (2016)) Show Alignments
Olaratumab 88 (Vergani et al., (2017)) 100 (Zhou et al., (2013)) 77 (Briney et al., (2019)) 100 (Doria-Rose et al., (2015)) 78 (Levin et al., (2017)) Show Alignments
Amatuximab 89 (Greiff et al., (2017)) 93 (Fisher et al., (2017)) 82 (Greiff et al., (2017)) 94 (Rettig et al., (2018)) 100 (Menzel et al., (2014)) Show Alignments
Tanezumab 82 (Corcoran et al., (2016)) 91 (Zhou et al., (2013)) 80 (Greiff et al., (2017)) 83 (Cui et al., (2016)) 86 (Greiff et al., (2017)) Show Alignments
Bezlotoxumab 92 (Vergani et al., (2017)) 100 (Doria-Rose et al., (2015)) 89 (Briney et al., (2019)) 100 (Doria-Rose et al., (2015)) 91 (Briney et al., (2019)) Show Alignments
Evolocumab 90 (Vander Heiden et al., (2017)) 96 (Gupta et al., (2017)) 91 (Briney et al., (2019)) 90 (Gupta et al., (2017)) 100 (Levin et al., (2017)) Show Alignments
Fasinumab 94 (Wu et al., (2011)) 93 (Soto et al., (2016)) 89 (Briney et al., (2019)) 88 (Schanz et al., (2014)) 83 (Galson et al., (2016)) Show Alignments
Infliximab 89 (Collins et al., (2015)) 93 (Rettig et al., (2018)) 75 (Greiff et al., (2017)) 83 (Huang et al., (2016)) 90 (Corcoran et al., (2016)) Show Alignments
Pamrevlumab 86 (Meng et al., (2017)) 100 (Zhou et al., (2013)) 82 (Galson et al., (2015)) 100 (Gupta et al., (2017)) 92 (Briney et al., (2019)) Show Alignments
Atezolizumab 85 (Vergani et al., (2017)) 89 (Corcoran et al., (2016)) 77 (Greiff et al., (2017)) 77 (Cui et al., (2016)) 90 (Galson et al., (2016)) Show Alignments
Ozanezumab 83 (Vergani et al., (2017)) 90 (Cui et al., (2016)) 90 (Greiff et al., (2017)) 100 (Cui et al., (2016)) 83 (Greiff et al., (2017)) Show Alignments
Pinatuzumab 81 (Schanz et al., (2014)) 86 (Schanz et al., (2014)) 89 (Greiff et al., (2017)) 86 (Cui et al., (2016)) 100 (Greiff et al., (2017)) Show Alignments
Quilizumab 87 (Greiff et al., (2017)) 86 (Schanz et al., (2014)) 88 (Greiff et al., (2017)) 91 (Cui et al., (2016)) 100 (Greiff et al., (2015)) Show Alignments
Lintuzumab 85 (Wu et al., (2015)) 87 (Wu et al., (2015)) 96 (Greiff et al., (2015)) 100 (Cui et al., (2016)) 100 (Greiff et al., (2017)) Show Alignments
Ublituximab 94 (Prohaska et al., (2018)) 96 (Rettig et al., (2018)) 96 (Greiff et al., (2017)) 88 (Cui et al., (2016)) 100 (Prohaska et al., (2018)) Show Alignments
Evinacumab 89 (Vergani et al., (2017)) 100 (Vander Heiden et al., (2017)) 91 (Briney et al., (2019)) 100 (Gupta et al., (2017)) 94 (Briney et al., (2019)) Show Alignments
Lirilumab 92 (Vergani et al., (2017)) 99 (Doria-Rose et al., (2015)) 84 (Setliff et al., (2018)) 100 (Doria-Rose et al., (2015)) 87 (Tipton et al., (2015)) Show Alignments
Timolumab 90 (Vergani et al., (2017)) 97 (Doria-Rose et al., (2015)) 80 (Ellebedy et al., (2016)) 100 (Doria-Rose et al., (2015)) 100 (Briney et al., (2019)) Show Alignments
Obinutuzumab 83 (Wu et al., (2011)) 91 (Rettig et al., (2018)) 78 (Greiff et al., (2015)) 100 (Cui et al., (2016)) 83 (Greiff et al., (2017)) Show Alignments
Zanolimumab 94 (Corcoran et al., (2016)) 99 (Soto et al., (2016)) 100 (Briney et al., (2019)) 100 (Gupta et al., (2017)) 100 (Levin et al., (2017)) Show Alignments
Matuzumab 83 (Greiff et al., (2017)) 85 (Corcoran et al., (2016)) 83 (Greiff et al., (2017)) 88 (Cui et al., (2016)) 92 (Greiff et al., (2017)) Show Alignments
Pateclizumab 74 (Vergani et al., (2017)) 91 (Zhou et al., (2013)) 81 (Corcoran et al., (2016)) 88 (Zhou et al., (2013)) 81 (Greiff et al., (2017)) Show Alignments
Suvratoxumab 93 (Vergani et al., (2017)) 98 (Zhou et al., (2013)) 87 (Meng et al., (2017)) 94 (Sheng et al., (2017)) 87 (Briney et al., (2019)) Show Alignments
Robatumumab 86 (Vergani et al., (2017)) 87 (Zhu et al., (2013)) 77 (Meng et al., (2017)) 100 (Gupta et al., (2017)) 91 (Tipton et al., (2015)) Show Alignments
Coltuximab 86 (Greiff et al., (2017)) 92 (Rettig et al., (2018)) 96 (Greiff et al., (2017)) 86 (Fisher et al., (2017)) 100 (Greiff et al., (2015)) Show Alignments
Sirukumab 82 (Vergani et al., (2017)) 88 (Doria-Rose et al., (2015)) 75 (Greiff et al., (2017)) 82 (Cui et al., (2016)) 83 (Rubelt et al., (2016)) Show Alignments
Rilotumumab 96 (Vergani et al., (2017)) 98 (Gupta et al., (2017)) 93 (Galson et al., (2015)) 94 (Doria-Rose et al., (2015)) 100 (Galson et al., (2015)) Show Alignments
Foralumab 90 (Corcoran et al., (2016)) 100 (Doria-Rose et al., (2015)) 81 (Briney et al., (2019)) 100 (Doria-Rose et al., (2015)) 90 (Briney et al., (2019)) Show Alignments
Dupilumab 87 (Palanichamy et al., (2014)) 97 (Soto et al., (2016)) 76 (Briney et al., (2019)) 95 (Doria-Rose et al., (2015)) 72 (Briney et al., (2019)) Show Alignments
Anifrolumab 91 (Vergani et al., (2017)) 96 (Huang et al., (2016)) 84 (Ellebedy et al., (2016)) 89 (Doria-Rose et al., (2015)) 90 (Jiang et al., (2013)) Show Alignments
Mepolizumab 72 (Palanichamy et al., (2014)) 92 (Gupta et al., (2017)) 78 (Greiff et al., (2017)) 95 (Cui et al., (2016)) 84 (Setliff et al., (2018)) Show Alignments
Visilizumab 85 (Greiff et al., (2017)) 88 (Soto et al., (2016)) 89 (Greiff et al., (2017)) 100 (Cui et al., (2016)) 100 (Prohaska et al., (2018)) Show Alignments
Tisotumab 92 (Vergani et al., (2017)) 97 (Soto et al., (2016)) 81 (Briney et al., (2019)) 100 (Huang et al., (2016)) 81 (Levin et al., (2017)) Show Alignments
Spartalizumab 77 (Tipton et al., (2015)) 83 (Sheng et al., (2017)) 76 (Greiff et al., (2017)) 91 (Cui et al., (2016)) 90 (Greiff et al., (2017)) Show Alignments
Tildrakizumab 84 (Vergani et al., (2017)) 87 (Corcoran et al., (2016)) 92 (Greiff et al., (2017)) 100 (Cui et al., (2016)) 100 (Prohaska et al., (2018)) Show Alignments
Motavizumab 83 (Corcoran et al., (2016)) 85 (Huang et al., (2016)) 75 (Corcoran et al., (2016)) 88 (Cui et al., (2016)) 83 (Greiff et al., (2017)) Show Alignments
Canakinumab 92 (Gupta et al., (2017)) 99 (Gupta et al., (2017)) 85 (Levin et al., (2017)) 100 (Gupta et al., (2017)) 100 (Briney et al., (2019)) Show Alignments
Camrelizumab 89 (Vergani et al., (2017)) 90 (Zhou et al., (2013)) 92 (Greiff et al., (2017)) 88 (Cui et al., (2016)) 100 (Collins et al., (2015)) Show Alignments
Ravulizumab 80 (Vergani et al., (2017)) 87 (Gupta et al., (2017)) 77 (Greiff et al., (2017)) 100 (Cui et al., (2016)) 86 (Greiff et al., (2017)) Show Alignments
Setrusumab 90 (Gupta et al., (2017)) 91 (Doria-Rose et al., (2015)) 84 (Briney et al., (2019)) 78 (Doria-Rose et al., (2015)) 90 (Greiff et al., (2015)) Show Alignments
Codrituzumab 84 (Vergani et al., (2017)) 91 (Cui et al., (2016)) 83 (Greiff et al., (2017)) 91 (Cui et al., (2016)) 87 (Greiff et al., (2017)) Show Alignments
Eculizumab 81 (Vergani et al., (2017)) 87 (Gupta et al., (2017)) 83 (Greiff et al., (2017)) 100 (Cui et al., (2016)) 86 (Greiff et al., (2017)) Show Alignments
Vatelizumab 80 (Greiff et al., (2017)) 79 (Gupta et al., (2017)) 82 (Greiff et al., (2015)) 88 (Fisher et al., (2017)) 92 (Greiff et al., (2017)) Show Alignments
Inclacumab 92 (Vergani et al., (2017)) 100 (Doria-Rose et al., (2015)) 75 (Briney et al., (2019)) 100 (Doria-Rose et al., (2015)) 88 (Briney et al., (2019)) Show Alignments
Eptinezumab 81 (Joyce et al., (2016)) 80 (Zhou et al., (2013)) 70 (Palanichamy et al., (2014)) 29 (Sheng et al., (2017)) 100 (Levin et al., (2017)) Show Alignments
Basiliximab 93 (Pei et al., (2017)) 97 (Rettig et al., (2018)) 88 (Greiff et al., (2017)) 93 (Cui et al., (2016)) 90 (Greiff et al., (2017)) Show Alignments
Ixekizumab 83 (Halliley et al., (2015)) 90 (Zhou et al., (2013)) 78 (Greiff et al., (2017)) 91 (Fisher et al., (2017)) 75 (Galson et al., (2015)) Show Alignments
Refanezumab 86 (Vander Heiden et al., (2017)) 96 (Gupta et al., (2017)) 80 (Corcoran et al., (2016)) 100 (Cui et al., (2016)) 73 (Greiff et al., (2017)) Show Alignments
Lebrikizumab 79 (Vergani et al., (2017)) 85 (Cui et al., (2016)) 74 (Collins et al., (2015)) 95 (Cui et al., (2016)) 91 (Khan et al., (2016)) Show Alignments
Carotuximab 95 (Khan et al., (2016)) 100 (Cui et al., (2016)) 85 (Greiff et al., (2017)) 100 (Cui et al., (2016)) 77 (Levin et al., (2017)) Show Alignments
Itolizumab 90 (Greiff et al., (2017)) 90 (Rettig et al., (2018)) 82 (Greiff et al., (2017)) 88 (Cui et al., (2016)) 83 (Greiff et al., (2015)) Show Alignments
Trastuzumab 83 (Mroczek et al., (2014)) 89 (Corcoran et al., (2016)) 82 (Greiff et al., (2017)) 94 (Ota et al., (2010)) 84 (Khan et al., (2016)) Show Alignments
Lanadelumab 86 (Vergani et al., (2017)) 100 (Schanz et al., (2014)) 67 (Galson et al., (2015)) 100 (Doria-Rose et al., (2015)) 73 (Briney et al., (2019)) Show Alignments
Landogrozumab 86 (Vergani et al., (2017)) 89 (Wu et al., (2015)) 81 (VanDuijn et al., (2017)) 89 (Cui et al., (2016)) 100 (Levin et al., (2017)) Show Alignments
Tomuzotuximab 90 (Menzel et al., (2014)) 97 (Cui et al., (2016)) 82 (Greiff et al., (2017)) 94 (Rettig et al., (2018)) 92 (Greiff et al., (2017)) Show Alignments
Ranibizumab 73 (Vergani et al., (2017)) 92 (Schanz et al., (2014)) 81 (Collins et al., (2015)) 88 (Ota et al., (2010)) 93 (Greiff et al., (2017)) Show Alignments
Galiximab 86 (Sundling et al., (2014)) 94 (Corcoran et al., (2016)) 58 (Sundling et al., (2014)) 90 (Corcoran et al., (2016)) 63 (Galson et al., (2015)) Show Alignments
Blosozumab 80 (Vergani et al., (2017)) 88 (Soto et al., (2016)) 66 (Greiff et al., (2017)) 88 (Cui et al., (2016)) 81 (Collins et al., (2015)) Show Alignments
Daclizumab 86 (Tipton et al., (2015)) 87 (Zhou et al., (2013)) 92 (Greiff et al., (2017)) 88 (Cui et al., (2016)) 100 (Levin et al., (2017)) Show Alignments
Andecaliximab 82 (Khan et al., (2016)) 85 (Zhu et al., (2013)) 87 (Greiff et al., (2017)) 77 (Cui et al., (2016)) 100 (Corcoran et al., (2016)) Show Alignments
Dacetuzumab 76 (Palanichamy et al., (2014)) 84 (Wu et al., (2015)) 82 (Greiff et al., (2017)) 91 (Cui et al., (2016)) 85 (Greiff et al., (2015)) Show Alignments
Pembrolizumab 80 (Tipton et al., (2015)) 86 (Gupta et al., (2017)) 86 (Greiff et al., (2017)) 90 (Cui et al., (2016)) 84 (Greiff et al., (2015)) Show Alignments
Emapalumab 97 (Vergani et al., (2017)) 99 (Doria-Rose et al., (2015)) 93 (Briney et al., (2019)) 95 (Doria-Rose et al., (2015)) 87 (Briney et al., (2019)) Show Alignments
Olendalizumab 87 (Vergani et al., (2017)) 88 (Zhou et al., (2013)) 75 (Greiff et al., (2017)) 100 (Cui et al., (2016)) 92 (Greiff et al., (2017)) Show Alignments
Fremanezumab 80 (Palanichamy et al., (2014)) 87 (Gupta et al., (2017)) 67 (Greiff et al., (2017)) 77 (Cui et al., (2016)) 53 (Galson et al., (2015)) Show Alignments
Gevokizumab 84 (Corcoran et al., (2016)) 86 (Corcoran et al., (2016)) 79 (Collins et al., (2015)) 88 (Cui et al., (2016)) 75 (Khan et al., (2016)) Show Alignments
Obiltoxaximab 87 (Greiff et al., (2017)) 85 (Rettig et al., (2018)) 100 (Greiff et al., (2017)) 100 (Cui et al., (2016)) 100 (Greiff et al., (2015)) Show Alignments
Siltuximab 92 (Collins et al., (2015)) 99 (Cui et al., (2016)) 89 (Greiff et al., (2017)) 100 (Cui et al., (2016)) 91 (Corcoran et al., (2016)) Show Alignments
Panitumumab 90 (Vergani et al., (2017)) 97 (Schanz et al., (2014)) 89 (Doria-Rose et al., (2015)) 94 (Zhou et al., (2013)) 90 (Levin et al., (2017)) Show Alignments
Solanezumab 89 (Vergani et al., (2017)) 92 (Zhou et al., (2013)) 80 (Meng et al., (2017)) 91 (Fisher et al., (2017)) 100 (Prohaska et al., (2018)) Show Alignments
Vadastuximab 81 (Greiff et al., (2017)) 88 (Wesemann et al., (2013)) 88 (Greiff et al., (2015)) 100 (Cui et al., (2016)) 100 (Greiff et al., (2017)) Show Alignments
Aducanumab 90 (Vergani et al., (2017)) 100 (Soto et al., (2016)) 78 (Setliff et al., (2018)) 100 (Doria-Rose et al., (2015)) 88 (Briney et al., (2019)) Show Alignments
Fletikumab 86 (Vander Heiden et al., (2017)) 100 (Doria-Rose et al., (2015)) 80 (Briney et al., (2019)) 100 (Doria-Rose et al., (2015)) 85 (Tipton et al., (2015)) Show Alignments
Dalotuzumab 85 (Vergani et al., (2017)) 91 (Soto et al., (2016)) 80 (Greiff et al., (2015)) 100 (Cui et al., (2016)) 90 (Corcoran et al., (2016)) Show Alignments
Briakinumab 91 (Vergani et al., (2017)) 88 (Doria-Rose et al., (2015)) 87 (Tipton et al., (2015)) 65 (Bhiman et al., (2015)) 75 (Greiff et al., (2017)) Show Alignments
Racotumomab 97 (Greiff et al., (2017)) 100 (Rettig et al., (2018)) 90 (Greiff et al., (2014)) 100 (Cui et al., (2016)) 92 (Galson et al., (2015)) Show Alignments
Foravirumab 94 (Vergani et al., (2017)) 98 (Wu et al., (2015)) 89 (Galson et al., (2015)) 100 (Soto et al., (2016)) 100 (Briney et al., (2019)) Show Alignments
Adalimumab 90 (Vergani et al., (2017)) 97 (Zhou et al., (2013)) 80 (Briney et al., (2019)) 94 (Gupta et al., (2017)) 71 (Levin et al., (2017)) Show Alignments
Galcanezumab 81 (Vergani et al., (2017)) 90 (Zhu et al., (2013)) 75 (Greiff et al., (2017)) 83 (Cui et al., (2016)) 83 (Galson et al., (2015)) Show Alignments
Opicinumab 90 (Vergani et al., (2017)) 98 (Zhou et al., (2013)) 77 (Meng et al., (2017)) 100 (Doria-Rose et al., (2015)) 90 (Tipton et al., (2015)) Show Alignments
Rituximab 94 (Corcoran et al., (2016)) 97 (Rettig et al., (2018)) 90 (Greiff et al., (2017)) 94 (Cui et al., (2016)) 85 (Greiff et al., (2017)) Show Alignments
Ganitumab 96 (Vergani et al., (2017)) 99 (Zhou et al., (2013)) 92 (Briney et al., (2019)) 100 (Huang et al., (2016)) 91 (Briney et al., (2019)) Show Alignments
Gemtuzumab 77 (Khan et al., (2016)) 83 (Gupta et al., (2017)) 80 (Greiff et al., (2017)) 86 (Cui et al., (2016)) 88 (Greiff et al., (2017)) Show Alignments
Abrilumab 92 (Palanichamy et al., (2014)) 97 (Zhou et al., (2013)) 85 (Briney et al., (2019)) 100 (Gupta et al., (2017)) 90 (Levin et al., (2017)) Show Alignments
Rovalpituzumab 86 (Palanichamy et al., (2014)) 90 (Zhou et al., (2013)) 88 (Khan et al., (2016)) 94 (Cui et al., (2016)) 90 (Levin et al., (2017)) Show Alignments
Dinutuximab 87 (Greiff et al., (2015)) 90 (Fisher et al., (2017)) 86 (Greiff et al., (2017)) 95 (Cui et al., (2016)) 83 (Prohaska et al., (2018)) Show Alignments
Tregalizumab 76 (Vergani et al., (2017)) 84 (Huang et al., (2016)) 72 (Corcoran et al., (2016)) 100 (Cui et al., (2016)) 93 (Greiff et al., (2017)) Show Alignments
Isatuximab 86 (Greiff et al., (2017)) 91 (Wesemann et al., (2013)) 89 (Greiff et al., (2017)) 94 (Cui et al., (2016)) 92 (Tipton et al., (2015)) Show Alignments
Icrucumab 90 (Vergani et al., (2017)) 100 (Doria-Rose et al., (2015)) 82 (Vergani et al., (2017)) 100 (Doria-Rose et al., (2015)) 78 (Ellebedy et al., (2016)) Show Alignments
Onartuzumab 78 (Vergani et al., (2017)) 85 (Corcoran et al., (2016)) 78 (Greiff et al., (2017)) 87 (Cui et al., (2016)) 75 (Levin et al., (2017)) Show Alignments
Enokizumab 86 (Wu et al., (2015)) 87 (Zhu et al., (2013)) 80 (Greiff et al., (2017)) 72 (Vander Heiden et al., (2017)) 86 (Prohaska et al., (2018)) Show Alignments
Zalutumumab 93 (Vergani et al., (2017)) 98 (Zhou et al., (2013)) 85 (Vander Heiden et al., (2017)) 100 (Doria-Rose et al., (2015)) 88 (Briney et al., (2019)) Show Alignments
Crenezumab 88 (Palanichamy et al., (2014)) 91 (Soto et al., (2016)) 95 (Greiff et al., (2015)) 100 (Fisher et al., (2017)) 100 (Prohaska et al., (2018)) Show Alignments
Ontuxizumab 69 (Corcoran et al., (2016)) 85 (Zhou et al., (2013)) 78 (Corcoran et al., (2016)) 84 (Cui et al., (2016)) 82 (Greiff et al., (2017)) Show Alignments
Certolizumab 79 (Vergani et al., (2017)) 87 (Zhou et al., (2013)) 81 (Collins et al., (2015)) 100 (Cui et al., (2016)) 100 (Greiff et al., (2015)) Show Alignments
Brodalumab 95 (Wu et al., (2015)) 96 (Vander Heiden et al., (2017)) 88 (Briney et al., (2019)) 100 (Gupta et al., (2017)) 100 (Greiff et al., (2017)) Show Alignments
Dectrekumab 94 (Soto et al., (2016)) 96 (Doria-Rose et al., (2015)) 93 (Briney et al., (2019)) 95 (Doria-Rose et al., (2015)) 100 (Briney et al., (2019)) Show Alignments
Urelumab 88 (Corcoran et al., (2016)) 100 (Doria-Rose et al., (2015)) 80 (Levin et al., (2017)) 100 (Doria-Rose et al., (2015)) 86 (Briney et al., (2019)) Show Alignments
Teprotumumab 86 (Vergani et al., (2017)) 98 (Schanz et al., (2014)) 85 (Galson et al., (2015)) 100 (Gupta et al., (2017)) 90 (Levin et al., (2017)) Show Alignments
Modotuximab 93 (Greiff et al., (2017)) 100 (Rettig et al., (2018)) 82 (Greiff et al., (2017)) 100 (Cui et al., (2016)) 91 (Greiff et al., (2017)) Show Alignments
Girentuximab 91 (Greiff et al., (2017)) 95 (Wesemann et al., (2013)) 78 (Greiff et al., (2017)) 88 (Ota et al., (2010)) 91 (Greiff et al., (2017)) Show Alignments
Ramucirumab 95 (Gupta et al., (2017)) 87 (Zhou et al., (2013)) 100 (Briney et al., (2019)) 88 (Zhou et al., (2013)) 100 (Levin et al., (2017)) Show Alignments
Ficlatuzumab 81 (Vergani et al., (2017)) 86 (Cui et al., (2016)) 81 (Collins et al., (2015)) 88 (Cui et al., (2016)) 90 (Greiff et al., (2017)) Show Alignments
Carlumab 92 (Vergani et al., (2017)) 92 (Schanz et al., (2014)) 82 (Sheng et al., (2017)) 70 (Gupta et al., (2017)) 83 (Greiff et al., (2017)) Show Alignments
Fezakinumab 85 (Tipton et al., (2015)) 96 (Schanz et al., (2014)) 70 (Galson et al., (2015)) 95 (Gupta et al., (2017)) 71 (Levin et al., (2017)) Show Alignments
Bococizumab 85 (Palanichamy et al., (2014)) 89 (Zhou et al., (2013)) 77 (Galson et al., (2015)) 83 (Schanz et al., (2014)) 81 (Corcoran et al., (2016)) Show Alignments
Lacnotuzumab 86 (Collins et al., (2015)) 85 (Rettig et al., (2018)) 88 (Greiff et al., (2017)) 94 (Cui et al., (2016)) 90 (Greiff et al., (2017)) Show Alignments
Bapineuzumab 88 (Vergani et al., (2017)) 91 (Rettig et al., (2018)) 75 (Greiff et al., (2017)) 100 (Cui et al., (2016)) 83 (Greiff et al., (2017)) Show Alignments
Nivolumab 89 (Corcoran et al., (2016)) 100 (Gupta et al., (2017)) 77 (Briney et al., (2019)) 100 (Gupta et al., (2017)) 100 (Greiff et al., (2017)) Show Alignments
Seribantumab 91 (Vergani et al., (2017)) 95 (Gupta et al., (2017)) 78 (Briney et al., (2019)) 95 (Gupta et al., (2017)) 83 (Levin et al., (2017)) Show Alignments
Alirocumab 88 (Vergani et al., (2017)) 96 (Zhou et al., (2013)) 85 (Briney et al., (2019)) 95 (Schanz et al., (2014)) 90 (Briney et al., (2019)) Show Alignments
Ponezumab 83 (Schanz et al., (2014)) 89 (Zhou et al., (2013)) 64 (Greiff et al., (2017)) 78 (Cui et al., (2016)) 77 (Tipton et al., (2015)) Show Alignments
Ustekinumab 86 (Vergani et al., (2017)) 99 (Soto et al., (2016)) 78 (Briney et al., (2019)) 100 (Vander Heiden et al., (2017)) 83 (Meng et al., (2017)) Show Alignments
Glembatumumab 91 (Vergani et al., (2017)) 99 (Wu et al., (2015)) 92 (Meng et al., (2017)) 100 (Gupta et al., (2017)) 100 (Galson et al., (2015)) Show Alignments
Orticumab 88 (Soto et al., (2016)) 92 (Zhu et al., (2013)) 73 (VanDuijn et al., (2017)) 77 (Bhiman et al., (2015)) 78 (Corcoran et al., (2016)) Show Alignments
Rafivirumab 87 (Vergani et al., (2017)) 95 (Gupta et al., (2017)) 75 (Briney et al., (2019)) 83 (Vander Heiden et al., (2017)) 70 (Galson et al., (2015)) Show Alignments
Mogamulizumab 84 (Vergani et al., (2017)) 88 (Schanz et al., (2014)) 67 (Greiff et al., (2017)) 78 (Cui et al., (2016)) 75 (Greiff et al., (2015)) Show Alignments
Tralokinumab 90 (Tipton et al., (2015)) 95 (Soto et al., (2016)) 80 (Galson et al., (2015)) 85 (Sheng et al., (2017)) 80 (Levin et al., (2017)) Show Alignments
Dusigitumab 94 (Vergani et al., (2017)) 97 (Gupta et al., (2017)) 100 (Briney et al., (2019)) 86 (Doria-Rose et al., (2015)) 100 (Levin et al., (2017)) Show Alignments
Parsatuzumab 77 (Vergani et al., (2017)) 86 (Zhou et al., (2013)) 81 (Corcoran et al., (2016)) 82 (Corcoran et al., (2016)) 93 (Greiff et al., (2017)) Show Alignments
Natalizumab 81 (Corcoran et al., (2016)) 87 (Rettig et al., (2018)) 90 (Greiff et al., (2017)) 100 (Cui et al., (2016)) 100 (Greiff et al., (2017)) Show Alignments
Lifastuzumab 83 (Vergani et al., (2017)) 84 (Schanz et al., (2014)) 65 (Galson et al., (2016)) 78 (Ota et al., (2010)) 76 (Levin et al., (2017)) Show Alignments
Rozanolixizumab 85 (VanDuijn et al., (2017)) 82 (Zhou et al., (2013)) 73 (Tipton et al., (2015)) 82 (Cui et al., (2016)) 80 (Greiff et al., (2017)) Show Alignments
Bavituximab 93 (Greiff et al., (2017)) 98 (Rettig et al., (2018)) 82 (Greiff et al., (2017)) 94 (Cui et al., (2016)) 92 (Greiff et al., (2017)) Show Alignments
Avelumab 89 (Vergani et al., (2017)) 100 (Doria-Rose et al., (2015)) 75 (Tipton et al., (2015)) 100 (Bhiman et al., (2015)) 84 (Jiang et al., (2013)) Show Alignments
Ocrelizumab 82 (Rubelt et al., (2016)) 88 (Zhou et al., (2013)) 93 (Greiff et al., (2017)) 94 (Cui et al., (2016)) 93 (Prohaska et al., (2018)) Show Alignments
Vonlerolizumab 77 (Tipton et al., (2015)) 92 (Schanz et al., (2014)) 65 (Corcoran et al., (2016)) 94 (Cui et al., (2016)) 80 (Corcoran et al., (2016)) Show Alignments
Ensituximab 90 (Greiff et al., (2017)) 94 (Rettig et al., (2018)) 81 (Greiff et al., (2014)) 94 (Cui et al., (2016)) 85 (Prohaska et al., (2018)) Show Alignments
Bimekizumab 85 (VanDuijn et al., (2017)) 84 (Vander Heiden et al., (2017)) 67 (VanDuijn et al., (2017)) 66 (Gupta et al., (2017)) 66 (Collins et al., (2015)) Show Alignments
Satralizumab 79 (Vergani et al., (2017)) 84 (Schanz et al., (2014)) 71 (Collins et al., (2015)) 72 (Cui et al., (2016)) 83 (Corcoran et al., (2016)) Show Alignments
Romosozumab 85 (Vergani et al., (2017)) 93 (Gupta et al., (2017)) 84 (Greiff et al., (2017)) 100 (Cui et al., (2016)) 81 (Greiff et al., (2017)) Show Alignments
Pritoxaximab 91 (Greiff et al., (2017)) 96 (Rettig et al., (2018)) 80 (Greiff et al., (2017)) 100 (Cui et al., (2016)) 80 (Briney et al., (2019)) Show Alignments
Iratumumab 91 (Rubelt et al., (2016)) 98 (Vander Heiden et al., (2017)) 85 (Briney et al., (2019)) 100 (Gupta et al., (2017)) 100 (Levin et al., (2017)) Show Alignments
Bimagrumab 89 (Tipton et al., (2015)) 92 (Doria-Rose et al., (2015)) 87 (Briney et al., (2019)) 73 (Gupta et al., (2017)) 100 (Prohaska et al., (2018)) Show Alignments
Pertuzumab 80 (Vergani et al., (2017)) 88 (Soto et al., (2016)) 75 (Corcoran et al., (2016)) 83 (Huang et al., (2016)) 91 (Briney et al., (2019)) Show Alignments
Belimumab 80 (Vergani et al., (2017)) 98 (Soto et al., (2016)) 62 (Ellebedy et al., (2016)) 100 (Gupta et al., (2017)) 62 (Greiff et al., (2017)) Show Alignments
Emibetuzumab 90 (Vergani et al., (2017)) 87 (Soto et al., (2016)) 87 (Greiff et al., (2017)) 94 (Cui et al., (2016)) 100 (Greiff et al., (2017)) Show Alignments
Sifalimumab 93 (Tipton et al., (2015)) 100 (Zhou et al., (2013)) 88 (Galson et al., (2016)) 100 (Doria-Rose et al., (2015)) 100 (Briney et al., (2019)) Show Alignments
Zolbetuximab 96 (Greiff et al., (2017)) 100 (Rettig et al., (2018)) 88 (Greiff et al., (2015)) 100 (Cui et al., (2016)) 81 (Levin et al., (2017)) Show Alignments
Inebilizumab 83 (Vergani et al., (2017)) 84 (Gupta et al., (2017)) 90 (Greiff et al., (2017)) 90 (Cui et al., (2016)) 92 (Greiff et al., (2017)) Show Alignments
Tovetumab 92 (Corcoran et al., (2016)) 90 (Soto et al., (2016)) 86 (Galson et al., (2015)) 89 (Gupta et al., (2017)) 92 (Galson et al., (2015)) Show Alignments
Pidilizumab 80 (Gupta et al., (2017)) 82 (Fisher et al., (2017)) 76 (Corcoran et al., (2016)) 94 (Cui et al., (2016)) 90 (Levin et al., (2017)) Show Alignments
Necitumumab 94 (Liao et al., (2013)) 95 (Zhou et al., (2013)) 93 (Levin et al., (2015)) 94 (Schanz et al., (2014)) 92 (Levin et al., (2017)) Show Alignments
Otlertuzumab 86 (Vergani et al., (2017)) 90 (Huang et al., (2016)) 92 (Greiff et al., (2017)) 77 (Cui et al., (2016)) 88 (Levin et al., (2017)) Show Alignments
Tezepelumab 90 (Corcoran et al., (2016)) 98 (Gupta et al., (2017)) 80 (Galson et al., (2015)) 100 (Gupta et al., (2017)) 80 (Palanichamy et al., (2014)) Show Alignments
Mavrilimumab 89 (Vergani et al., (2017)) 91 (Vander Heiden et al., (2017)) 72 (Briney et al., (2019)) 73 (Doria-Rose et al., (2015)) 61 (Galson et al., (2015)) Show Alignments
Ofatumumab 92 (Palanichamy et al., (2014)) 100 (Doria-Rose et al., (2015)) 90 (Galson et al., (2015)) 100 (Doria-Rose et al., (2015)) 93 (Briney et al., (2019)) Show Alignments
Actoxumab 87 (Corcoran et al., (2016)) 100 (Gupta et al., (2017)) 83 (Galson et al., (2015)) 100 (Doria-Rose et al., (2015)) 86 (Galson et al., (2015)) Show Alignments
Tislelizumab 86 (Sheng et al., (2017)) 86 (Schanz et al., (2014)) 88 (Greiff et al., (2017)) 83 (Cui et al., (2016)) 91 (Greiff et al., (2015)) Show Alignments
Etrolizumab 83 (Vergani et al., (2017)) 89 (Corcoran et al., (2016)) 76 (Greiff et al., (2017)) 72 (Wu et al., (2015)) 100 (VanDuijn et al., (2017)) Show Alignments
Plozalizumab 84 (Vergani et al., (2017)) 91 (Soto et al., (2016)) 73 (Greiff et al., (2017)) 100 (Cui et al., (2016)) 87 (Greiff et al., (2017)) Show Alignments
Teplizumab 74 (Vergani et al., (2017)) 82 (Corcoran et al., (2016)) 82 (Greiff et al., (2017)) 100 (Cui et al., (2016)) 83 (Greiff et al., (2017)) Show Alignments
Abagovomab 91 (Greiff et al., (2017)) 90 (Fisher et al., (2017)) 89 (Greiff et al., (2017)) 94 (Ota et al., (2010)) 100 (Greiff et al., (2015)) Show Alignments
Varlilumab 95 (Corcoran et al., (2016)) 98 (Zhou et al., (2013)) 89 (Vergani et al., (2017)) 100 (Huang et al., (2016)) 91 (Briney et al., (2019)) Show Alignments
Lumiliximab 81 (Vergani et al., (2017)) 94 (Vander Heiden et al., (2017)) 59 (Briney et al., (2019)) 83 (Soto et al., (2016)) 88 (Greiff et al., (2017)) Show Alignments
Duligotuzumab 81 (Mroczek et al., (2014)) 90 (Zhu et al., (2013)) 63 (Greiff et al., (2017)) 77 (Huang et al., (2016)) 78 (Greiff et al., (2017)) Show Alignments
Atidortoxumab 89 (Vergani et al., (2017)) 98 (Sheng et al., (2017)) 67 (Jiang et al., (2013)) 88 (Corcoran et al., (2016)) 83 (Ellebedy et al., (2016)) Show Alignments
Lodelcizumab 85 (Palanichamy et al., (2014)) 88 (Schanz et al., (2014)) 70 (Greiff et al., (2017)) 70 (Cui et al., (2016)) 90 (Khan et al., (2016)) Show Alignments
Gantenerumab 88 (Vergani et al., (2017)) 94 (Sheng et al., (2017)) 68 (Briney et al., (2019)) 89 (Schanz et al., (2014)) 63 (Briney et al., (2019)) Show Alignments
Tigatuzumab 89 (Vergani et al., (2017)) 87 (Corcoran et al., (2016)) 89 (Greiff et al., (2017)) 100 (Cui et al., (2016)) 83 (Greiff et al., (2017)) Show Alignments
Ipilimumab 91 (Vergani et al., (2017)) 99 (Zhou et al., (2013)) 88 (Briney et al., (2019)) 100 (Zhou et al., (2013)) 90 (Levin et al., (2017)) Show Alignments
Inotuzumab 80 (Soto et al., (2016)) 82 (Cui et al., (2016)) 80 (Collins et al., (2015)) 95 (Cui et al., (2016)) 100 (Collins et al., (2015)) Show Alignments
Fulranumab 90 (Vander Heiden et al., (2017)) 100 (Doria-Rose et al., (2015)) 78 (Briney et al., (2019)) 100 (Doria-Rose et al., (2015)) 93 (Briney et al., (2019)) Show Alignments
Lampalizumab 87 (Vergani et al., (2017)) 83 (Zhou et al., (2013)) 79 (Corcoran et al., (2016)) 94 (Cui et al., (2016)) 75 (Tipton et al., (2015)) Show Alignments
Elotuzumab 90 (Greiff et al., (2017)) 87 (Vander Heiden et al., (2017)) 96 (Greiff et al., (2015)) 100 (Wesemann et al., (2013)) 100 (Greiff et al., (2017)) Show Alignments
Radretumab 93 (Soto et al., (2016)) 96 (Wu et al., (2015)) 80 (Galson et al., (2015)) 84 (Zhou et al., (2013)) 100 (Greiff et al., (2017)) Show Alignments
Cetuximab 91 (Menzel et al., (2014)) 97 (Cui et al., (2016)) 82 (Greiff et al., (2017)) 94 (Rettig et al., (2018)) 92 (Greiff et al., (2017)) Show Alignments
Burosumab 91 (Palanichamy et al., (2014)) 97 (Gupta et al., (2017)) 80 (Briney et al., (2019)) 94 (Doria-Rose et al., (2015)) 90 (Palanichamy et al., (2014)) Show Alignments
Secukinumab 88 (Vergani et al., (2017)) 100 (Gupta et al., (2017)) 80 (Briney et al., (2019)) 100 (Doria-Rose et al., (2015)) 80 (Galson et al., (2015)) Show Alignments
Trevogrumab 87 (Palanichamy et al., (2014)) 94 (Doria-Rose et al., (2015)) 79 (Briney et al., (2019)) 88 (Doria-Rose et al., (2015)) 69 (Tipton et al., (2015)) Show Alignments
Palivizumab 82 (Corcoran et al., (2016)) 84 (Gupta et al., (2017)) 86 (Greiff et al., (2017)) 94 (Fisher et al., (2017)) 100 (Greiff et al., (2017)) Show Alignments
Mirikizumab 81 (Vergani et al., (2017)) 88 (Vander Heiden et al., (2017)) 83 (Corcoran et al., (2016)) 77 (Cui et al., (2016)) 87 (Levin et al., (2015)) Show Alignments
Intetumumab 90 (Sheng et al., (2017)) 100 (Doria-Rose et al., (2015)) 85 (Briney et al., (2019)) 100 (Doria-Rose et al., (2015)) 91 (Galson et al., (2015)) Show Alignments
Muromonab 94 (Khan et al., (2016)) 97 (Cui et al., (2016)) 82 (Greiff et al., (2017)) 100 (Cui et al., (2016)) 83 (Greiff et al., (2017)) Show Alignments
Risankizumab 79 (Vergani et al., (2017)) 83 (Zhou et al., (2013)) 82 (Greiff et al., (2017)) 83 (Ota et al., (2010)) 84 (Greiff et al., (2017)) Show Alignments
Reslizumab 78 (Soto et al., (2016)) 89 (Zhou et al., (2013)) 92 (VanDuijn et al., (2017)) 77 (Gupta et al., (2017)) 100 (Corcoran et al., (2016)) Show Alignments
Mirvetuximab 87 (Greiff et al., (2017)) 90 (Wesemann et al., (2013)) 77 (Greiff et al., (2014)) 100 (Wesemann et al., (2013)) 90 (Corcoran et al., (2016)) Show Alignments
Tesidolumab 92 (Vergani et al., (2017)) 87 (Soto et al., (2016)) 92 (Briney et al., (2019)) 65 (Bhiman et al., (2015)) 100 (Galson et al., (2015)) Show Alignments
Sacituzumab 84 (Corcoran et al., (2016)) 85 (Corcoran et al., (2016)) 96 (Corcoran et al., (2016)) 94 (Rettig et al., (2018)) 100 (Pei et al., (2017)) Show Alignments